Chester County News and Community Website
PHILADELPHIA, PA & MALVERN, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) and OrthoCellix, Inc. have announced a definitive merger agreement to combine the two companies in an all-stock transaction. The …
Carisma Therapeutics and OrthoCellix Merge to Advance Regenerative Cell Therapy for Orthopedic Diseases Read More
PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced a revised operating plan as it evaluates a range of strategic alternatives. The plan is aimed at preserving resources, reducing …
Carisma Therapeutics Focuses on Strategic Alternatives Amid Revised Operating Plan Read More PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced that Michael Klichinsky, PharmD, PhD, Co-founder and Chief Scientific Officer, will present at the H.C. Wainwright 3rd Annual Cell Therapy …
Michael Klichinsky to Speak at H.C. Wainwright Cell Therapy Virtual Conference Read More PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced that Steven Kelly, President and Chief Executive Officer, will represent the company at the Oppenheimer 35th Annual Healthcare Life Sciences …
Carisma Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Conference Read More PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) announced a strategic realignment of its resources, discontinuing the development of its CT-0525 program and reducing its workforce by 34%. These decisions are …
Carisma Therapeutics Refocuses Strategy, Reduces Workforce Amid Pipeline Reprioritization Read More PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM), in collaboration with Moderna, Inc. (Nasdaq: MRNA), has announced promising pre-clinical results for their innovative anti-GPC3 chimeric antigen receptor macrophage (CAR-M) therapy targeting …
Carisma Therapeutics and Moderna Unveil Promising Pre-Clinical Data for Anti-GPC3 CAR-M Therapy Read More PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced its financial results for the third quarter of 2024, alongside significant progress in its clinical and preclinical programs. The company …
Carisma Therapeutics Reports Q3 2024 Results, Advances Clinical Programs Read More PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced a key addition to its Board of Directors with the appointment of Sohanya Cheng, effective October 31, 2024. Concurrently, Michael …
Carisma Therapeutics Welcomes Sohanya Cheng to Board of Directors Read More PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has broadened its collaboration with Moderna, Inc. (Nasdaq: MRNA) to focus on developing treatments for autoimmune diseases, marking a significant step in leveraging …
Carisma Therapeutics and Moderna Expand Partnership to Target Autoimmune Diseases Read More PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) released its financial results for the second quarter ended June 30, 2024. The company also provided updates on its ongoing clinical and …
Carisma Therapeutics Reports Progress and Financial Results for Q2 2024 Read More